Objective.-We studied 8 triathletes competing in the 3-day World Ultraman Championships (day 1: 10-km swim, 165-km bike; day 2: 261-km bike; day 3: 85-km run) to determine the effect of extreme physical exertion on heart rate (HR), mean arterial blood pressure (MAP) and pulmonary function, and their relation to overall athletic performance.
Introduction
The triathlon is a demanding competition involving endurance performances in swimming, biking, and running. Standard race distances range from sprint-length races (800-m swim, 20-km bike, and 5-km run) to shortcourse triathlons (1.5-km swim, 40-km bike, and 10-km run; also known as the ''Olympic distance'') and Ironman events consisting of a 3.8-km swim, 180-km bike, and 42.2-km run. In addition to these standard distances, there are substantially longer distance events such as the World Ultraman Championships held in Hawaii. This is a 3-day staged-race triathlon that requires competitors to swim 10 km and bike 165 km on the first day, bike 261 km on the second day, and finish with an 85-km run on the third day.
Biochemical and physiological changes induced by triathlon performance have been reviewed. 1,2 These reviews cover studies of triathlon performance from shortcourse through Ironman distances. Although no cardiopulmonary studies investigating triathletes racing beyond the Ironman distances have been reported, previous research of ultramarathon 3 and wilderness multisport endurance competitions 4 has shown substantial declines in respiratory function.
The purpose of the present study was to document basic heart rate (HR), mean arterial blood pressure (MAP) and pulmonary function characteristics during an event requiring extreme physical endurance through monitoring of ultradistance triathletes during the 3-day World Ultraman Championships and to relate these characteristics to overall race performance. We hypothesized that the extreme nature of this multiday competition might produce more marked changes in pulmonary function, and that these would be strongly related to overall race performance.
Methods

SUBJECTS
Subjects were recruited from athletes entered in the World Ultraman Championships (Kona, Hawaii). The Institutional Ethics Review Board of Simon Fraser University approved the study, and written informed consent was obtained from all subjects. None of the athletes had a history of cardiovascular or pulmonary disease, and preliminary respiratory measures conformed to spirometric tables of normal respiratory function. 5 
RACE CONDITIONS
The start times for days 1 and 3 were at 6:00 AM, whereas the start time for day 2 was at 6:30 AM. At the start of the 10-km swimming portion of the race on day 1, water temperature was 24ЊC and air temperature was 35ЊC. By the end of the 165-km bike stage on day 1, the riders had reached an altitude of 1220 m and the air temperature was 21ЊC. On day 2 the air temperature ranged from 15ЊC to 37ЊC as the last 261-km phase of the cycling portion returned to sea level. On day 3, the 85-km sea-level run segment of the race was relatively flat with temperatures ranging from 17ЊC in the morning to 37ЊC at finish time. Humidity ranged from 70% on day 1 to 50% on day 3. During the race the athletes had unrestricted access to fluids and food from roadside stations and from race-support vehicles traveling with the racers. None of the 8 subjects required medical attention during or after any stage of the race.
DATA COLLECTION
All measurements were made with the subject seated on the back of a crew vehicle. Pulmonary measures were collected with an automated SpiroPro pulmonary function unit (Jaeger Toenneis GmbH, Hoechberg, Germany). This device is manufactured according to American Thoracic Society guidelines. The spirometer was calibrated immediately before the testing with a precision 3-L flow-volume syringe (MultiFlow, Pulmonary Data Service Instrumentation, Louisville, CO). Tests with the syringe after the competition indicated no change in calibration. The measurements included forced vital capacity (FVC), forced expiratory volume in 1 second (FEV 1.0 ), and peak expiratory flow (PEF). Before the data collection, athletes practiced the pulmonary function test until maximal reproducible ventilatory efforts were within 5% of each other. Pulmonary function measures were performed 2 days before the competition between 10:00 AM and noon and within 5 minutes of the completion of each day of the competition. The best of 3 efforts was recorded.
Baseline cardiovascular measures of HR and MAP were made with a digital automated oscillometric blood pressure monitor (A&D Medical, Milpitas, CA). Two measurements were obtained and averaged for analysis. These measurements were collected 2 days before competition between 10:00 AM and noon. None of the subjects had exercised within 24 hours of the measurement and had not eaten or consumed caffeinated or alcoholic beverages within 2 hours of this test. No such restrictions were placed on the prerace tests that were made less than 30 minutes before the start on each day of the triathlon. End-of-day measures were performed after the pulmonary measures and within 10 minutes of completion of each stage with the subject seated on the back of a crew vehicle within 50 m of the finish line. Pulmonary cardiovascular measures were not performed after the swim discipline because of the transition time constraint associated with moving from the swim stage to the bike stage.
STATISTICS
The JMP-IN statistical package (SAS Institute Inc., Cary, NC) was used for all statistical analysis. Repeatedmeasures analysis of variance was used to compare variables during all the race days. All data are quoted as mean Ϯ SEM. Linear regression analysis was made among all collected variables for each group member and their recorded total race times. Significance was accepted at P Ͻ .05. To determine significant prerace day correlates of race performance, baseline cardiovascular and pulmonary data were compared with total swim, bike, and run times by using multiple regression analysis previously described in Blaber et al. 5 
Results
Twelve subjects of a total field of 32 agreed to participate in the study. A sudden change in the water currents and in the weather during the swim on day 1 adversely affected some of the competitors, and because of the cutoff time imposed upon the swim section, 4 of our volunteer athletes were classed as nonfinishers. Data from the remaining 8 subjects were used for analysis. Their mean age was 35.8 years (range 24-42 years), mean weight was 75 kg (range 69-84 kg), and mean height was 180 cm (range 174-182 cm). None of the racers was a smoker or had asthma. Their finishing positions ranged from 1st to 16th. Individual race performance data for these subjects are presented in Table 1 .
PHYSIOLOGICAL MEASUREMENTS
Pulmonary
Baseline measures were not significantly different from predicted 6 values (Table 2 ). Immediately after completion of the swim and bike stages on day 1 there was a significant reduction in FVC, FEV 1.0 , and PEF (Table 2) compared with baseline, and FVC and FEV 1.0 were also reduced after day 2 (P Ͻ .05 for all). A significant further reduction in FVC and FEV 1.0 was observed postday 3 compared with post-day 1 ( Table 2) .
Cardiovascular
Baseline HR collected 2 days before the race (56.5 Ϯ 1.5 beats/min) was at least 9 beats/min lower than the HRs recorded within 30 minutes of the start of each race day (P Ͻ .005 for all) ( Figure 1 ). All postrace HRs were significantly higher than prerace values (P Ͻ .005 for all). The prerace day 2 and postrace day 3 HRs were also significantly higher than the corresponding values on day 1 (P Ͻ .05 for both). The mean baseline resting MAP was 103 Ϯ 3.1 mm Hg, with the highest mean value being observed immediately before the start of the first stage (110 Ϯ 2.0 mm Hg). The lowest race MAP was recorded on day 3 immediately after completion of the run (91 mm Hg). Prerace MAP was significantly higher than baseline on day 1 and lower on day 2 (P Ͻ .05 for both) ( Figure  1 ).
CORRELATIONS WITH TOTAL RACE TIME
Linear regression analysis of cardiopulmonary function data indicated a lower baseline resting HR (r ϭ 0.77, P ϭ .021) significantly correlated with a faster total race time. A lower MAP immediately before the race on day Baseline cardiopulmonary data were used in a multiple regression analysis for predictors of total race time (TRT). When only baseline data were used, heart rate (HR) and mean arterial pressure (MAP) were combined to produce the best prediction.
1 was also indicative of a better total race time (r ϭ 0.67, P ϭ .036). No baseline pulmonary or other cardiovascular data were significantly associated with performance.
Linear regression analysis of the change in cardiopulmonary function (difference between baseline and final value on day 3) with total race time in each athlete indicated a negative correlation for FEV 1.0 and PEF (Figure 2) . Changes in HR and MAP were not associated with total race time.
Multiple regression analysis of baseline physiological data with respect to total race time elucidated some predictors of performance (Figure 3) . When only baseline physiological data were used, HR and MAP were found to have the greatest contribution to total race time pre-diction in decreasing order of contribution (54% and 19%, respectively; Figure 3 ). When changes in pulmonary function from baseline to postrace were added, the decrease in PEF became the only variable entered into the model and accounted for 87% of the variance. This gave a result that was the same as presented in Figure  2b .
Discussion
To our knowledge, this is the first study to investigate cardiopulmonary changes during a multiday ultratriathlon event and their possible relationship to performance. The 8 volunteer competitors who finished ranged from the 1st to 16th place. Thus, the athletes who were studied represented the performance elite among this exceptional group.
Pulmonary function measures all showed a decline from baseline to postrace on day 3. Compared with baseline, both FVC and FEV 1.0 were reduced on all 3 race days, whereas PEF was reduced only on days 1 and 3. Similar reductions in flow rates have been documented for Ironman competitors 7 and after a wilderness multisport competition. 4, 8 Respiratory muscle fatigue could explain the diminished flow rates observed and has been documented after exercise if the intensity level is high or the duration is prolonged to exhaustion. 3, 7, 8 The further decline of FVC and FEV 1.0 on day 3 could be due to both performing the more cardiorespiratory-demanding 85-km run to near exhaustion on day 3 and the cumulative effects of 3 days of fatiguing competition. Respiratory muscle fatigue induced before high-intensity exercise has been shown to reduce subsequent performance. 9 Notwithstanding the small sample size, we observed a relatively strong correlation of decrements in pulmonary flow rates with total performance as well as a strong predictive association (87%) of the reduction in PEF, from baseline to race finish, to total race time.
The reduction observed in FVC after each day has also been documented after completion of a marathon 10 and Ironman triathlon. 7 Respiratory muscle fatigue could also explain the lung volume reduction. Weaker respiratory muscles would fail to expand or reduce thoracic volume against the large elastic counter forces at each extreme of lung volume. Some studies indicate a higher residual volume after long-duration running, suggesting the presence of an expiratory limitation. 10 The athletes' average baseline HR was 56.5 Ϯ 1.5 beats/min. Within 30 minutes before the start of each day of racing, the average HR was elevated (Figure 1) . The anticipatory excitement of the race would certainly account for the elevation. As would be expected, within 5 minutes of finishing each day, HR was still elevated above prerace levels. The largest pre-to postchanges in HR and MAP occurred on day 3. This was not surprising because the run not only was the most physically demanding of the 3 stages but also was the last stage and therefore the final event to improve race position. Furthermore, even though the athletes were allowed to hydrate at will during the race, there may have been a tendency for a decrease in intravascular volume during the run compared with the previous stages of the race, which could have led to a greater increase in HR.
Mean arterial pressure, compared with baseline, was elevated half an hour before the start of the competition on day 1. A similar observation was made before a 100-km ultramarathon. 3 There was also a significant positive correlation between MAP at the beginning of day 1 and total race time but not on any other days, whereas baseline HR, and not day 1 HR, was positively correlated with total race time. Elevated MAP could also be attributed to race anxiety or anticipation, yet only day 1 MAP, not day 1 HR, correlated with total race time just before the start of the competition.
After 3 days and more than 22 hours of intense exercise in air temperatures up to 37ЊC, the Ultraman triathletes displayed a substantial reduction in pulmonary function. The degree of PEF and FEV 1.0 decrements, along with baseline resting HR and MAP, were predictive of the overall ranking in the triathlon. The most significant finding was the multiple regression result indicating that the decrease in PEF was associated with 87% of total race time correlation. This association, though just correlative, suggests a link between pulmonary function and ultratriathlon performance. This study was limited in its inability to utilize perturbations and continuous measurements to make a more causal relation between pulmonary function and performance, as these highly competitive elite athletes were unwilling to make large time commitments or perform activities that could have impeded their performance. However, these data do provide evidence to further pursue, in laboratory and field conditions, the interrelationship between pulmonary function and physical performance in events or situations that require extreme aerobic and physical endurance.
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